Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry
-
* Corresponding author: Marta Salido MSALIDO@IMAS.IMIM.ES
Breast Cancer Res 2005, 7:R267-R273 doi:10.1186/bcr996
Accesses
- Last 30 days: 125 accesses
- Last year: 1264 accesses
- All time: 10022 accesses
Cited by
BioMed Central: 2 citations
|
Methodology
Hiroaki Nitta, Beatrice Hauss-Wegrzyniak, Megan Lehrkamp, Adrian E Murillo, Fabien Gaire, Michael Farrell, Eric Walk, Frederique Penault-Llorca, Masafumi Kurosumi, Manfred Dietel, Lin Wang, Margaret Loftus, James Pettay, Raymond R Tubbs, Thomas M Grogan Diagnostic Pathology 2008, 3:41 (22 October 2008) Automated brightfield double in situ hybridization for simultaneous detection of Her-2 gene and chromosome 17 centromere shows promise as an improved method for selecting breast cancer patients for trastuzumab therapy.
|
|
Research article
Andreea Nistor, Peter H Watson, Norman Pettigrew, Karim Tabiti, Angelika Dawson, Yvonne Myal BMC Clinical Pathology 2006, 6:2 (18 January 2006) A real-time polymerase chain reaction test for determining the status of Her-s/neu amplification in breast cancer is comparable to fluorescent in-situ hybridization in cases found where the standard immunohistochemical method is indeterminate.
|